程序性细胞死亡蛋白-1及其配体抑制剂免疫相关不良反应的中医治疗方药初探

Preliminary exploration of traditional Chinese medicine prescriptions for immune-related adverse reactions of programmed cell death protein-1 and its ligand inhibitors

程序性细胞死亡蛋白-1及其配体(PD-1/PD-L1)抑制剂是近年来治疗肿瘤的重要手段,但其引起的皮肤、消化道等不良反应严重影响了肿瘤患者的治疗连续性和生活质量。虽然目前缺少中医药改善由PD-1/PD-L1抑制剂引起的免疫相关不良反应的相关临床研究,但基于整体观和辨证论治的中医药在改善各类肿瘤治疗不良反应方面具有独特的优势,文章尝试分析总结PD-1/PD-L1抑制剂免疫相关不良反应的辨证分型,并讨论其临床对应的方药应用,旨在进一步提升肿瘤治疗的临床疗效和预后。

In recent years,programmed cell death-1 and its ligand(PD-1/PD-L1)inhibitors are important means of cancer treatment.However,adverse reactions such as skin and digestive tract seriously affect the continuity of treatment and the quality of life of cancer patients.The number of clinical studies of Traditional Chinese medicine(TCM)to improve the related adverse reactions caused by PD-1/PD-L1 inhibitors is insufficient.Based on a holistic view and syndrome differentiation,TCM has unique advantages in improving the adverse reactions of patients with various types of tumors after treatment.We attempt to analyze and summarize the syndrome differentiation of PD-1/PD-L1 inhibitors related to adverse reactions,and discuss the corresponding clinical prescription application,aiming to improve the efficacy and prognosis of this cancer therapy.